The Russell 2000 (^RUT), comprised of small-cap stocks, presents investors with the potential for significant returns, but also carries heightened volatility and risk due to the vulnerability of smaller companies during economic downturns. Navigating this segment of the market effectively requires careful analysis, which is why StockStory was developed to identify promising companies and those facing challenges. This article highlights three Russell 2000 stocks – two that investors should consider selling and one that warrants close attention – offering insights into their respective strengths and weaknesses. Jack in the Box (JACK) is a fast-food chain with a distinctive brand, but recent performance indicators raise concerns. QuidelOrtho (QDEL), a diagnostic testing solutions provider, has experienced revenue disappointments and declining profitability. Conversely, Astrana Health (ASTH), formerly Apollo Medical Holdings, is attracting attention due to its technology-powered healthcare platform and notable revenue growth, showcasing a compelling market opportunity.
Jack in the Box (JACK) presents a situation that warrants cautious consideration. The company’s market capitalization stands at $365.3 million, and it operates a well-known fast-food chain characterized by bold flavors and innovative offerings. However, over the past two years, same-store sales performance has been poor, signaling difficulty attracting new customers. Furthermore, operating expenses have risen as a percentage of revenue, resulting in a 6.5 percentage point decline in the operating margin. The company’s current net-debt-to-EBITDA ratio of 11 indicates lenders are less willing to extend additional capital, potentially leading to dilutive equity offerings. With a stock price of $19.21, Jack in the Box trades at a valuation of 5.1x forward P/E. A full research report, accessible to active Edge members, provides a more detailed analysis of these concerns.
QuidelOrtho (QDEL) presents a separate set of challenges. With a market capitalization of $1.89 billion, this diagnostic testing solutions provider emerged from the 2022 merger of Quidel and Ortho Clinical Diagnostics. Despite its significant operations, the company has faced consistent currency revenue growth disappointments over the past two years, indicating soft demand. Free cash flow margins have dropped by 27.6 percentage points over the last five years, indicating the company has become more capital intensive due to increased competition. Additionally, eroding returns on capital from an already low base suggest that management’s recent investments are not generating value. At $28.01 per share, QuidelOrtho trades at 13.1x forward P/E. A free in-depth research report is available to understand why QDEL doesn’t meet the firm’s investment criteria.
Astrana Health (ASTH) is a compelling stock within the Russell 2000, with a market capitalization of $1.14 billion. Formerly known as Apollo Medical Holdings, the company operates a technology-powered healthcare platform facilitating coordinated care and participation in value-based payment models. The company’s impressive 47.7% annual revenue growth over the last two years demonstrates market share gains. The revenue outlook for the upcoming 12 months is strong, reinforcing this trend, and earnings growth has comfortably exceeded the peer group average over the last five years, with earnings per share compounding at 11.6% annually. At $22.41 per share, Astrana Health trades at a modest 4.3x forward EV-to-EBITDA ratio, suggesting an opportune moment to potentially initiate a position.
The potential for portfolio success relies heavily on identifying a select number of high-quality assets before market volatility increases and prices diminish. It’s crucial to act decisively rather than waiting for the next market shock. StockStory highlights a curated list of “High Quality” stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025), including companies like Nvidia (+1,326% between June 2020 and June 2025) and Exlservice (+354% five-year return). StockStory’s growth is supported by hiring equity analyst and marketing roles, specifically seeking individuals passionate about the markets and AI.